Dose debate: which rituximab regimen works best for rare blistering disease?

NCT ID NCT07457944

Completed Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 275 pemphigus patients to see how different doses of rituximab affected disease control and relapse. Pemphigus is a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers tracked outcomes like flare-ups, side effects, and steroid use to find the safest and most effective dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab
What this could lead to: If successful, this study could help doctors choose the best rituximab dose to control pemphigus with fewer side effects.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be less reliable. Rituximab can cause serious infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pemphigus pemphigus foliaceus pemphigus vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEMPHIGUS DISEASE RITUXIMAB (RTX)

Contacts and locations

Locations

Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.